Solasia Pharma (4597.T JPX) closed JPY 29.00 on 15 Jan 2026: active trade signals to watch
Solasia Pharma K.K. (4597.T) was one of the JPX’s most active names on 15 Jan 2026, closing at JPY 29.00 on volume of 33,559,200 shares as the market closed. The 4597.T stock shows a tight intraday range, with a day low of JPY 28.00 and day high of JPY 29.00, and trading remains well above the year low of JPY 27.00. Volume relative to the 50-day and 200-day averages suggests heightened retail and program interest. We summarise the drivers behind today’s liquidity, the fundamentals that matter, and what active traders should watch next
Market snapshot for 4597.T stock
4597.T stock closed at JPY 29.00 on JPX in Japan with a recorded volume of 33,559,200 shares, below the 50-day average volume of 43,419,869.00. The stock’s intraday range was JPY 28.00–29.00, and the 12-month span is JPY 27.00–48.00. One clear market fact: liquidity today placed the name on most-active lists, signalling traders are re-pricing short-term expectations for Solasia Pharma K.K.
Earnings, valuation and fundamentals (4597.T analysis)
Solasia reports EPS of -8.96 and a negative PE of -3.24, reflecting recent losses and development-stage revenue. Price-to-book is 4.19 and price-to-sales is 22.75, both above Healthcare peer averages. The company holds JPY 7.05 cash per share and a strong current ratio of 4.57, indicating balance sheet liquidity despite operating losses.
Technical and volume signals for active traders
Technicals show a neutral-to-weak bias: RSI 45.38, MACD histogram slightly positive at 0.11, and ATR 1.66, which points to limited near-term range. Bollinger Bands sit at JPY 26.39–32.51, placing current price inside the band. On-balance volume is materially negative, but today’s high turnover suggests stop and limit flows are moving price discovery.
Meyka AI rates 4597.T with a score out of 100
Meyka AI rates 4597.T with a score out of 100: 63.71 (Grade B, SUGGESTION: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights cash per share and R&D stage assets as strengths, and negative EPS plus elevated valuation multiples as weaknesses. These grades are informational and not financial advice.
Forecasts, price targets and analyst view (4597.T forecast)
Meyka AI’s forecast model projects a yearly price of JPY 23.50, implying a model-based downside of -18.97% versus the current JPY 29.00. The monthly projection is JPY 25.27 (implied -12.79%). For scenario planning we flag a conservative price target of JPY 22.00 (implied -24.14%) and an optimistic target of JPY 40.00 (implied +37.93%). Forecasts are model-based projections and not guarantees.
Risks, sector context and trading checklist
Solasia operates in Healthcare drug manufacturers where the sector average PE is about 24.03 and average current ratio 3.07; Solasia’s negative earnings and high price-to-sales ratio are outliers and heighten downside risk. Key catalysts to monitor are upcoming earnings on 13 Feb 2026, clinical updates for SP-05 and SP-02, and cash burn versus R&D milestones. Active traders should set tight risk limits given volatility and sparse analyst coverage.
Final Thoughts
Key takeaways on 4597.T stock: Solasia Pharma K.K. closed JPY 29.00 on 15 Jan 2026 with heavy trading that placed it on JPX most-active lists. Fundamentals show a stretched valuation versus peers (price-to-sales 22.75, price-to-book 4.19) and negative EPS -8.96, while the balance sheet retains cash per share of JPY 7.05. Meyka AI’s forecast model projects a yearly price of JPY 23.50, implying an estimated downside of -18.97% from today’s close; monthly projection is JPY 25.27. Our graded view (Meyka AI Grade B, HOLD) balances cash runway and development assets against continued operating losses and binary clinical risk. Active traders should watch volume spikes, the Feb 2026 earnings announcement, and clinical readouts as primary catalysts. For investors, consider position sizing that limits exposure to single-drug development risk and compare Solasia’s metrics to larger Healthcare peers on JPX. For more data and live alerts, see the Meyka AI stock page for 4597.T and the Bloomberg quote for market updates source. Forecasts are model-based projections and not guarantees.
FAQs
What drove 4597.T stock’s heavy trading on 15 Jan 2026?
High turnover occurred as traders repositioned ahead of clinical and earnings catalysts. Volume hit 33,559,200 shares, suggesting retail and program activity with price finishing at JPY 29.00 on JPX.
What is Meyka AI’s forecast for 4597.T stock?
Meyka AI’s forecast model projects a yearly price of JPY 23.50, implying -18.97% from the current JPY 29.00. Forecasts are model-based projections and not guarantees.
How do Solasia’s fundamentals compare to Healthcare peers?
Solasia shows negative EPS -8.96 and high price-to-sales 22.75, while Healthcare peers average PE around 24.03 and higher earnings stability, making Solasia an outlier with greater risk.
When is the next earnings or catalyst for 4597.T?
Solasia lists an earnings announcement on 13 Feb 2026. Clinical milestones for SP-05 and SP-02 are additional high-impact catalysts to monitor before and after that date.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
